Mechanisms of GII.4 Norovirus Evolution

Overview

Journal Trends Microbiol

Date 2011 Feb 12

PMID 21310617

Citations 84

Authors

Rowena A Bull

Peter A White

Affiliations

Soon will be listed here.

Abstract

Since the late 1990s norovirus (NoV) strains belonging to a single genotype (GII.4) have caused at least four global epidemics. To date, the higher epidemiological fitness of the GII.4 strains has been attributed to a faster rate of evolution within the virus capsid, resulting in the ability to escape herd immunity. Four key factors have been proposed to influence the rate of evolution in NoV. These include host receptor recognition, sequence space, duration of herd immunity, and replication kinetics. In this review we discuss recent advancements in our understanding of these four mechanisms in relation to GII.4 evolution.

Citing Articles

A new wave of resurgence for GII.4 Sydney in Huzhou, particularly GII.4 Sydney[P16], between 2019 and 2023.

Zhu X, Zhang P, Yan W, Dong F, Xu D, Yuan R BMC Infect Dis. 2025; 25(1):241.

PMID: 39972255 PMC: 11841341. DOI: 10.1186/s12879-025-10648-5.

Molecular Characterization of Enteric Viruses Causing Acute Gastroenteritis among Children under 5 Years Old in Distrito Central, Honduras.

Ortiz-Quintero J, Cabrera Y, Bourdett-Stanziola L, Ferrera A Intervirology. 2024; 67(1):83-98.

PMID: 38981462 PMC: 11326528. DOI: 10.1159/000540253.

Development of a broad-spectrum therapeutic Fc-nanobody for human noroviruses.

Hansman G, Kher G, Svirina A, Tame J, Hartley-Tassell L, Irie H J Virol. 2024; 98(7):e0070724.

PMID: 38953655 PMC: 11264634. DOI: 10.1128/jvi.00707-24.

Noroviruses: Evolutionary Dynamics, Epidemiology, Pathogenesis, and Vaccine Advances-A Comprehensive Review.

Omatola C, Mshelbwala P, Okolo M, Onoja A, Abraham J, Adaji D Vaccines (Basel). 2024; 12(6).

PMID: 38932319 PMC: 11209302. DOI: 10.3390/vaccines12060590.

A narrative review of norovirus epidemiology, biology, and challenges to vaccine development.

Carlson K, Dilley A, OGrady T, Johnson J, Lopman B, Viscidi E NPJ Vaccines. 2024; 9(1):94.

PMID: 38811605 PMC: 11137017. DOI: 10.1038/s41541-024-00884-2.